A Phase I Dose Escalation Study of IMRT Field-in-field Boost for Newly Diagnosed Glioblastoma Multiforme (GBM)
Arta M. Monjazeb(University of California Davis Medical Center), Edward G. Shaw(Wake Forest University), Michael T. Munley(Radiation Oncology Associates), Stephen B. Tatter(Atrium Health Wake Forest Baptist), J. Daniel Bourland(Wake Forest University), Kevin P. McMullen(Radiation Oncology Associates), Glenn J. Lesser(Virginia Commonwealth University), Thomas L. Ellis(Wake Forest University), L. D. Case(Wake Forest University)
International Journal of Radiation Oncology*Biology*Physics
August 21, 2008
Cited by 0
Related Papers
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
|New England Journal of Medicine|2016|1k
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
|Nature Communications|2022|243
Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and counterfactual reward
|Proceedings of the National Academy of Sciences|2015|239
Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis
|Journal of neurosurgery|2010|173